ArticleISRN oncology2012

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.

Olav Engebraaten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.